We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here are three stocks with buy rank and strong value characteristics for investors to consider today, November 13th:
Mr. Cooper Group Inc. (COOP - Free Report) : This company that provides servicing, origination, and transaction-based services related principally to single-family residences has a Zacks Rank #1 (Strong Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 56.8% over the last 60 days.
Danaos Corporation (DAC - Free Report) : This company that owns and operates containerships in Australia, Asia, Europe, and the United States has a Zacks Rank #2 (Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 3.8% over the last 90 days.
Lexicon Pharmaceuticals, Inc. (LXRX - Free Report) : This biopharmaceutical company has a Zacks Rank #2, and seen the Zacks Consensus Estimate for its current year earnings rising 10.1% over the last 60 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Top Ranked Value Stocks to Buy for November 13th
Here are three stocks with buy rank and strong value characteristics for investors to consider today, November 13th:
Mr. Cooper Group Inc. (COOP - Free Report) : This company that provides servicing, origination, and transaction-based services related principally to single-family residences has a Zacks Rank #1 (Strong Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 56.8% over the last 60 days.
MR. COOPER GROUP INC Price and Consensus
MR. COOPER GROUP INC price-consensus-chart | MR. COOPER GROUP INC Quote
Mr. Cooper Group has a price-to-earnings ratio (P/E) of 3.64, compared with 8 for the industry. The company possesses a Value Score of A.
MR. COOPER GROUP INC PE Ratio (TTM)
MR. COOPER GROUP INC pe-ratio-ttm | MR. COOPER GROUP INC Quote
Danaos Corporation (DAC - Free Report) : This company that owns and operates containerships in Australia, Asia, Europe, and the United States has a Zacks Rank #2 (Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 3.8% over the last 90 days.
Danaos Corporation Price and Consensus
Danaos Corporation price-consensus-chart | Danaos Corporation Quote
Danaos has a price-to-earnings ratio (P/E) of 1.22, compared with 7.3 for the industry. The company possesses a Value Score of A.
Danaos Corporation PE Ratio (TTM)
Danaos Corporation pe-ratio-ttm | Danaos Corporation Quote
Lexicon Pharmaceuticals, Inc. (LXRX - Free Report) : This biopharmaceutical company has a Zacks Rank #2, and seen the Zacks Consensus Estimate for its current year earnings rising 10.1% over the last 60 days.
Lexicon Pharmaceuticals, Inc. Price and Consensus
Lexicon Pharmaceuticals, Inc. price-consensus-chart | Lexicon Pharmaceuticals, Inc. Quote
Lexicon Pharmaceuticals has a price-to-earnings ratio (P/E) of 4.62, compared with 20.3 for the industry. The company possesses a Value Score of B.
Lexicon Pharmaceuticals, Inc. PE Ratio (TTM)
Lexicon Pharmaceuticals, Inc. pe-ratio-ttm | Lexicon Pharmaceuticals, Inc. Quote
See the full list of top ranked stocks here.
Learn more about the Value score and how it is calculated here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>